{"protocolSection":{"identificationModule":{"nctId":"NCT04664946","orgStudyIdInfo":{"id":"k（2020）31"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)","officialTitle":"Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-12-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-05-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-05-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-11-30","studyFirstSubmitQcDate":"2020-12-06","studyFirstPostDateStruct":{"date":"2020-12-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-20","lastUpdatePostDateStruct":{"date":"2023-08-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Hui-Sheng Chen","investigatorTitle":"Director","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"Hui-Sheng Chen","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation."},"conditionsModule":{"conditions":["Ischemic Stroke","Neuroprotection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intra-arterial administration of 3-n-butylphthalide","type":"EXPERIMENTAL","description":"Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.","interventionNames":["Drug: Intra-arterial administration of neuroprotective agents"]}],"interventions":[{"type":"DRUG","name":"Intra-arterial administration of neuroprotective agents","description":"Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.","armGroupLabels":["Intra-arterial administration of 3-n-butylphthalide"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of server adverse events","description":"server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc.","timeFrame":"48 hours"}],"secondaryOutcomes":[{"measure":"Proportion of patients with modified Rankin Score 0 to 1","description":"Proportion of patients with modified Rankin Score 0 to 1","timeFrame":"90 days"},{"measure":"Proportion of patients with modified Rankin Score 0 to 2","description":"Proportion of patients with modified Rankin Score 0 to 2","timeFrame":"90 days"},{"measure":"Modified Rankin Score","description":"Modified Rankin Score","timeFrame":"90 days"},{"measure":"Decrease in national institutes of health stroke scale (NIHSS)","description":"Decrease in NIHSS scoring at 48 hours after the treatment","timeFrame":"48 hours"},{"measure":"Proportion of symptomatic intracranial hemorrhage (sICH)","description":"sICH was defined as 4 or more increase in NIHSS caused by hemorrhage","timeFrame":"48 hours"},{"measure":"Proportion of intraparenchymal hemorrhage (PH1 and PH2)","description":"Proportion of intraparenchymal hemorrhage (PH1 and PH2) within 48 hours after the treatment","timeFrame":"48 hours"},{"measure":"Changes in cerebral edema","description":"Cerebral edema was determined by cerebral volume or midline shift","timeFrame":"48 hours"},{"measure":"All causes of death within 48 hours after the treatment","description":"All causes of death within 48 hours after the treatment","timeFrame":"48 hours"},{"measure":"Differences in serum factors levels in different artery region","description":"Differences in serum factors levels in different Bessel region before recanalization","timeFrame":"0 hour"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Major neurologic deficits: 6≤NIHSS≤20;\n3. Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined as symptoms worsen in 48 hours (an increase in NIHSS more than 4);\n4. Premorbid mRS 0 or 1;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Patients who underwent intravenous thrombolysis or Endovascular treatment;\n3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \\<80000/mm3;\n4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n5. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n6. Unsuitable for this clinical studies assessed by researcher.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Department of Neurology, General Hospital of Northern Theater Command","city":"Shenyang","zip":"110016","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000018696","term":"Neuroprotective Agents"}],"ancestors":[{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M352286","name":"3-n-butylphthalide","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","asFound":"Over-the-counter (OTC)","relevance":"HIGH"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}